| Literature DB >> 35052517 |
Abrar Alhebshi1,2, Nehal Alsharif1,3, Josh Thorley1, Lewis J James1, Tom Clifford1.
Abstract
This systematic review examined the effects of whole protein and commonly consumed amino acid supplements on markers of exercise-induced inflammation and oxidative stress and was reported according to the PRISMA guidelines. MEDLINE and SPORTDiscus were searched from inception until June 2021. The inclusion criteria were randomized clinical trials in humans, healthy adult participants (≥18 years), dietary protein/amino acid interventions, and measurements of oxidative stress/the redox status or inflammation post-exercise. The Cochrane Collaboration risk of bias 2 tool was used to critically appraise the studies. Data extracted from thirty-four studies were included in the systematic review (totaling 757 participants with only 10 females; age range 19-40 years). The included trials examined five types of whole protein and seven different amino acids supplements; most studies (n = 20) failed to identify statistically significant effects on markers of inflammation or oxidative stress after exercise; some (n = 14) showed either anti-inflammatory or antioxidant effects on some, but not all, markers. In conclusion, we found weak and inconsistent evidence that dietary protein/amino acid interventions can modify exercise-induced changes in oxidative stress and inflammation. However, given that these were not the primary outcomes in many of the included studies and many had design limitations, further research is warranted (Open Science Framework registration number: 10.17605/OSF.IO/AGUR2).Entities:
Keywords: amino acids; exercise recovery; high intensity exercise; immunity; oxidative damage
Year: 2021 PMID: 35052517 PMCID: PMC8773319 DOI: 10.3390/antiox11010013
Source DB: PubMed Journal: Antioxidants (Basel) ISSN: 2076-3921
Figure 1PRISMA flow diagram of the literature search strategy.
Studies examining the effects of whole protein supplementation on markers of exercise-induced inflammation and oxidative stress. The Difference column denotes intervention vs. comparator.
| Study | Participants | Design | Intervention | Comparator | Timing of Supplement | Exercise | Outcomes | Difference |
|---|---|---|---|---|---|---|---|---|
| Baba et al. (2014) | 14 M | Crossover | Drink (22.8-g WPI, 4.4-g CHO) | Drink (5.2 g of the same minus WPI | Pre, during, and post-exercise | Plasma IL-6 | ↔ | |
| Betts et al. (2009) | 17 M | SB, | Drink (0.4-g.kg−1 BM·h−1 WPI, 1.2-g·kg−1 BM·h−1 CHO) | Drink (1.2-g·kg−1 BM·h−1 CHO) | During and ≤4 h post-exercise | 90 min LIST | Serum IL-6 | ↔ |
| Serum IL-10 | ↔ | |||||||
| Serum CRP | ↔ | |||||||
| Serum IL-1 ra | ↔ | |||||||
| Buckley et al. (2010) | 28 M | DB, | Drink | Drink (flavored water) | 0, 6 and 22 h post-exercise | 100 eccentric contractions of knee extensors | Plasma TNF-α | ↔ |
| Draganidis et al. (2017) | 11 M | DB, | Drink (20-g milk PRO) | Drink (20 g of maltodextrin) | 300 eccentric contractions of knee extensors | Muscle NF-κB | ↔ | |
| Muscle HSP70 | ↔ | |||||||
| Serum PC | ↓ | |||||||
| Leukocytes | ↔ | |||||||
| Grubic et al. (2019) | 12 M | Open label, Crossover | Food bar (20-g WP, 25-g IMO, 7-g fat) | Gel (25-g dextrose) | 30-min pre-, mid-way, and post-exercise | RT (3 × 10 reps at 70% of 1 RM) + agility and sprint drills | Serum IFNy | ↔ |
| Serum IL-13 | ↔ | |||||||
| Serum IL-1 β | ↔ | |||||||
| Serum IL-4 | ↔ | |||||||
| Serum IL-6 | ↔ | |||||||
| Serum IL-8 | ↔ | |||||||
| Serum TNF-α | ↔ | |||||||
| Hall et al. (2013) | 10 M | DB, | Drink (0.23-g·kg−1·h−1 casein + 0.1-g·kg−1·h−1 leucine + 0.87-g·kg−1·h−1 CHO) | CHO beverage (1.2 g·kg−1·h−1) | Every 15 min during exercise | 2.5-h intermittent cycling (30–90% Wmax) | Neutrophils | ↓ |
| Lymphocytes | ↓ | |||||||
| Hilkens et al. (2020) | INT: 20 M 24 ± 4 CON: 19 M, 23 ± 4 | DB, | Drink (58.5-g WP + 5.0-g CHO) | Drink (72-g CHO) | 2/day for 9 days pre- and post-exercise | 10 × 10 DJs with 5 kg vest | Plasma CRP | ↔ |
| Karakuş et al. (2020) | 22 ± 2 M | Parallel | 35-g WP drink | NR | 3 meals, 3 days post-exercise | RT (10 exercises for different body parts) | Neutrophils | ↔ |
| Platelets | ↔ | |||||||
| Leukocytes | ↔ | |||||||
| Lymphocytes | ↔ | |||||||
| Kerasioti et al. (2013) | 9 M | DB, | Cake (0.9-g·kg−1·h−1 CHO + 0.26-g·kg−1·h−1 WP) | Isocaloric cake (1.1-g·kg−1·h−1 CHO + 0.1-g·kg−1·h−1 WP) | Plasma IL-6 | ↓ 4 h post | ||
| Plasma IL-10 | ↔ | |||||||
| Plasma CRP | ↓ 4 h post | |||||||
| Kritikos et al. (2021) | 10 M | DB, | Drink (WPI or SOY)—enough to reach 1.5 g/kg/day | Drink (maltodextrin) | 1/day for 3 days | 60 min speed-endurance training | Glutathione | ↔ |
| Serum TAC | ↔ | |||||||
| Plasma PC | ↓ SOY vs. PL, 48 h | |||||||
| Naclerio et al. (2014) | 10 M | DB, | Drink (53-g CHO,14.5-g WP, 5-g glutamine, 1.5-g L-carnitine-L-tartrate) | Drink | 1 dose during exercise and 1 post-exercise | 90-min intermittent exercise | Plasma IL-6 | ↔ |
| Nieman et al. (2020) | Pea: 31 M | DB, | Drink | Drink (water) | 13 doses over 5 days on day of and post-exercise | 90-min eccentric exercise | Serum CRP | ↔ |
| Rankin et al. (2017) | 10 F | Crossover | Drink (17-g milk PRO; 25.5-g CHO) | Drink (52.6-g CHO) | <30 min post-exercise | Intermittent sprint cycling (~60 min) | Serum hsCRP | ↔ |
| Serum GSH/GSSG | ↔ | |||||||
| Serum PC | ↔ | |||||||
| Rothschild et al. (2021) | 17 M | Crossover | PRO-rich meal (0.45-g·kg−1 WPI + 0.24-g·kg−1 fat) | CHO-rich meal (1-g·kg−1 CHO) | 30 pre-exercises | HI cycling (~45 min) | Urinary F2-Isoprostanes | ↔ |
| Rowlands et al. (2016) | 12 M cyclists | SB, | Drink | Isocaloric drink (0-g WP, 274-g CHO, 30-g FAT). | HI cycling (70–90% Wmax,100 min) | * Muscle inflammatory-myogenic regenerative processes | ↑ | |
| Shenoy et al. (2016) | 40 M | DB, | Drink (21-g SOY, 21-mg isoflavones) | Drink (sweetened water) | 2/day for | 100 DJs | Plasma hsCRP | ↔ |
| Plasma MPO | ↔ | |||||||
| Wells et al. (2017) | 10 M | Crossover | Drink (Milk PRO 20-g AAs, 6-g CHO) | Drink (Flavored water, 2.5-g CHO) | Post-exercise | Lower body RT (10–12 reps at 70% 1 RM) | Plasma TNF-α | ↔ |
| TNFr1 expression on monocytes | ↔ | |||||||
| Wojcik et al. (2001) | 27 M | 3-arm parallel | Drink | Drink (sweetened water) | 2 × post-exercise | 100 eccentric contractions of knee flexors | Serum IL-6 | ↔ |
| Serum IL-1 | ↔ | |||||||
| Serum TNF | ↔ |
Data presented as mean ± SD. M = male; F = female; PL = placebo; CHO = carbohydrate; PRO = protein; WP = whey protein; WPI = whey protein isolate; SB = single-blinded, DB = double-blinded, BM = body mass; INT = intervention; CON = control; IL-6 = interleukin 6; IL-10 = interleukin 10; IL-1 = interleukin-1; IL-1 ra = interleukin-1 receptor antagonist; CRP = C-reactive protein; hsCRP = high sensitivity C-reactive protein IMO = isomalto-oligosaccharides; TNF = tumor necrosis factor; TNF-α = tumor necrosis factor-alpha; TNFr1 = expression of tumor necrosis factor receptor 1; MPO = myeloperoxidase; AA = amino acid; LEU = leucine; SOY = soy protein; TAC = total antioxidant capacity; NF-κB = nuclear factor kappa-B; HSP70 = 70 kilodalton heat shock proteins; NR = not reported; RT = resistance training; 1 RM = one-repetition maximum; reps = repetitions; IFNy = interferon gamma; IL-13 = interleukin 13; IL-1ß = interleukin-1-beta; IL-4 = interleukin 4; IL-8 = interleukin 8; PC = protein carbonyls; DJs = drop jumps; GSH/GSSG = reduced glutathione to oxidized glutathione ratio; HI = high intensity; LIST= Loughborough intermittent shuttle test; ↔ = no significant difference; ↓= significantly decreased responses; ↑ = significantly increased responses. * This study measured several hundreds of makers in muscle tissue, and thus, the general conclusion from the data is presented here instead.
Studies examining the effects of various amino acids on the markers of exercise-induced inflammation and oxidative stress. The Difference column denotes intervention vs. comparator.
| Study | Participants | Design | Intervention | Comparator | Timing of supplement | Exercise |
|
|
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| Jackman et al. (2010) | INT: 12 M | SB, Parallel | Drink (BCAA: 3.5-g LEU, 2 g of isoleucine, + 1.7 g of valine) | Drink (sweetened water) | 4/day on the day of and 3 days post-exercise | 120 eccentric knee extensions | Serum IL-6 | ↔ |
| Ra et al. (2013) | 36 M | DB, | Drink: | Starch (to match treatment volumes) | 3/day pre- and post- exercise for 18 days | Eccentric elbow flexor exercises (6 × 5 reps at 90% MVC) | Serum 8-OHdG | ↓ BCAA + taurine vs. BCAA + PL and PL |
| Takegaki et al. (2020) | INT: 10 M | DB, | Drink (5-g Leucine-enriched Aas) | Drink (water) | 2.5 g × 2, pre- and post-exercise | Lower body RT (3 × 10 reps at 70% of 1 RM) | IL-6 muscle mRNA | ↔ |
| IL-1β muscle mRNA | ↔ | |||||||
| Waskiw-Ford et al. (2020) | INT: 10 M | DB, | Drink (4 g of essential Aas) | Isocaloric CHO PL | 3/day, for 4 days post-exercise | Lower-body RT (5 × 9–12 reps at 75% of 1 RM) | Muscle HSP25 | ↔ |
| Plasma IL-6 | ↔ | |||||||
| Muscle HSP72 | ↓ | |||||||
| Wells et al. (2016) | 10 M | Crossover | Drink (20 g of milk | Drink (flavored water, 2.5-g CHO) | Post-exercise | Lower-body RT | Plasma MCP-1 | ↔ |
| CCR2 | ↔ | |||||||
| CD11 b | ↔ | |||||||
| CD14+ MON | ↔ | |||||||
| CD14 ++ CD16- MON | ↔ | |||||||
|
| ||||||||
| Wilson et al. (2013) | INT: 11 M | Parallel | Drink (3-g·day−1 HMB-FA) | Drink (sweetened water) | Pre- and post-exercise | Full body RT (3 × 12 reps) | Plasma CRP | ↔ |
|
| ||||||||
| Parandak et al. (2014) | INT: 10 M | DB, | Capsules (2-g L-carnitine) | Capsules (2-g lactose) | Daily for 2-wk pre-exercise | Serum TAC | ↑ 24 h post | |
| Serum TBARS | ↓ 24 h post | |||||||
| Volek et al. (2002) | 10 M | Crossover | Capsules (2-g·day−1 L-carnitine 944-mg·day−1 L-tartrate) | Capsules (cellulose) | Daily for 3-wk, pre and post-exercise | Lower body RT (5 × 15–20 reps at 50% of 1 RM) | Plasma MDA | ↓ at 15 min post |
| Plasma XO | ↓ at 0, 15, 180 min post | |||||||
|
| ||||||||
| Sureda et al. (2009) | 22 ± 4 | DB, Parallel | Drink (6-g citrulline-malate) | Drink (lemon juice) | 2 h pre-exercise | 137.1 km cycling | PMN-ROS | ↑ post |
| PMN-MDA | ↔ | |||||||
| DNA damage | ↔ | |||||||
|
| ||||||||
| Clifford et al. (2019) | INT: 12 M | DB, Parallel | Drink (20-g·day−1 CP) | Drink (20-g maltodextrin) | 10 g × 2, | 150 DJs | Leukocytes | ↔ |
| Neutrophils | ↔ | |||||||
| Monocytes | ↔ | |||||||
| Lymphocytes | ↔ | |||||||
| Serum IL-6 | ↔ | |||||||
|
| ||||||||
| Cury-Boaventura et al. (2008) | 9 M | DB, | Drink (2.8-g WP,+ | Drink (50-g maltodextrin) | 30 min pre-exercise | Treadmill running to exhaustion | DNA damage in leukocytes | ↔ |
| Neutrophil O2− | ↔ | |||||||
| Nakhostin-Roohi et al. (2017) | INT: 9 M | DB, | Drink (1.5-g·kg−1 BM·day−1 glutamine) | Drink (sweetened water) | 1/day for 7 days pre-exercise | Plasma TAC | ↔ | |
| plasma Glutathione | ↔ | |||||||
| Plasma MDA | ↔ | |||||||
| Nemati et al. (2019) | INT: 15 M 19.7 ± 2 | Parallel | Drink (0.3-g·kg−1 BM·day−1 glutamine + 25-g sugar) | Drink (25-g sugar) | 1/day for 14 days pre-exercise | Serum TAC | ↑ | |
| Serum MDA | ↓ | |||||||
| Serum hsCRP | ↓ | |||||||
| Glutathione | ↑ | |||||||
|
| ||||||||
| Da Silva et al. (2014) | 21 ± 6 | DB, Parallel | Capsules (Taurine 50-mg·kg BM−1·day−1) | Capsules (Starch 50-mg·kg BM−1·day−1) | 1/day, 14 days pre and 7 days post-exercise | Eccentric elbow flexion and extension exercise (3 × 11–15 reps at 80% of 1 RM) | Xylenol | ↓ |
| Plasma PC | ↓ | |||||||
| Plasma TT | ↑ | |||||||
| Erythrocyte-derived SOD | ↔ | |||||||
| Erythrocyte-derived CAT | ↔ | |||||||
| Erythrocyte-derived GPX | ↔ | |||||||
| Plasma TNF-α | ↔ | |||||||
| Plasma IL-1ß | ↔ | |||||||
| Plasma IL-10 | ↔ | |||||||
| Ra et al. (2016) | INT: 15 M | DB, | Powder (6-g taurine) | Powder (6-g lactose) | Daily for 14 days pre-, on, & 3 days post-exercise | Eccentric contractions of the elbow flexors (2 × 20 reps) | Serum MDA | ↓ 3 d, 4 d post |
| Zembron-Lacny et al. (2007) | INT: | 4-arm parallel | Drink | Drink | 3/day for 3 days pre-exercise | Full body RT (3 exercises in a circuit until exhaustion) | SOD | ↑ TAU vs. PL 24 h post |
| GPX | ↑ TAU vs. PL 24 h post | |||||||
| CAT | ↔ | |||||||
| Plasma Protein thiols | ↔ | |||||||
| TBARS | ↔ | |||||||
Data presented as mean ± SD. INT = intervention; CON = control; PL = placebo; M = male; F = female; SB = single-blinded, DB = double-blinded, BM = body mass; CHO = carbohydrate; PRO = protein; IL-6 = interleukin 6; MVC = maximal voluntary contraction; IL-1β = interleukin-1-beta; 1 RM = one-repetition maximum; reps = repetitions; HSP25 = heat shock proteins 25; HSP72 = heat shock protein 72; TNF-α = tumor necrosis factor-alpha; IL-10 = interleukin 10; HMB-FA = β-hydroxy-β-methylbutyrate free acid; BCAA = branched-chain amino acid; CAT = catalase; GPX = glutathione peroxidase; LEU = leucine; LIP, α-lipoic acid; MCP-1 = monocyte chemoattractant protein 1; CCR2 = chemokine receptor type 2; CRP = C-reactive protein; hsCRP = high sensitivity C-reactive protein; NAC = N-acetylcysteine; PC = protein carbonyls; PMNs = polymorphonuclear neutrophils; MDA = malondialdehyde; TAC = total antioxidant capacity; TAU = taurine; LIP = α-lipoic acid; DJs, drop jumps; ROS = reactive oxygen sepsis; RT = resistance training; SOY = soy protein; SOD = superoxide dismutase; TBARS = thiobarbituric acid-reactive substance; XO = xanthine oxidase; TT = total thiol content; Neutrophil O2− = superoxide production in neutrophils; CP = collagen peptides; 8-OHdG, 8-hydroxydeoxyguanosine; CD11 b = expression of macrophage-1 antigen in cluster of differentiation molecule 11 b; CD14+ MON = percent change in proportion of CD14+ monocytes relative to all leukocytes; CD14++CD16- MON = percent change in classical monocytes relative to all monocytes; ↔ = no significant difference; ↓ = significantly decreased responses; ↑ = significantly increased responses.
Figure 2Risk of bias graph for the parallel design trials.
Figure 3Risk of bias graph for the crossover trials.